Stevia Corp. Files Provisional Patent with the United States Patent and Trademark Office for the Treatment of Symptoms Associated with BPH (Benign Prostatic Hyperplasia)

Author's Avatar
Aug 08, 2022

NEW YORK, NY / ACCESSWIRE / August 8, 2022 / Stevia Corp. (OTC PINK:STEV) ("Stevia Corp" or the "Company"), a healthcare company focused on the commercial development of products that support a healthy lifestyle announced today that the company has filed a provisional patent with the United States Patent and Trademark Office for a proprietary herbal supplement formula for the treatment of BPH and symptoms related to BPH (Benign Prostatic Hyperplasia). At the present time and to protect the claims and integrity of the provisional patent, Stevia Corp. is not publicly identifying the components of the herbal supplement formula. The provisional patent was assigned application number 63/370,673 by the USPTO.